Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL44846 | 0.83 | TRPV1 (0.50) | TRPV1NPY5RTRPA1PTGS1EPHX2 | |
| SCHEMBL384694 | 0.82 | ALDH1A1 (0.45) | MEN1KMT2A | |
| SCHEMBL45318 | 0.80 | KMT2A (0.41) | MEN1KMT2A | |
| SCHEMBL10118261 | 0.79 | TRPV1 (0.45) | TRPV1NPY5R | |
| SCHEMBL10118252 | 0.79 | TRPV1 (0.43) | TRPV1NPY5R | |
| SCHEMBL44829 | 0.79 | TRPV1 (0.43) | TRPV1TRPA1KCNH2 | |
| SCHEMBL10118246 | 0.78 | TRPV1 (0.44) | TRPV1NPY5R | |
| SCHEMBL10118247 | 0.78 | TRPV1 (0.42) | TRPV1NPY5R | |
| SCHEMBL44880 | 0.77 | OPRL1 (0.41) | TRPV1TRPA1MEN1KMT2A | |
| SCHEMBL23249321 | 0.75 | DHODH (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582688-B1 | ANTHRANILIC ACID DIAMIDE DERIVATIVES | BAYER IP GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-8791139-B2 | Anthranilic diamide derivatives | BAYER CROPSCIENCE AG (DE) | 2014-07-29 | — | — | US | disclosed |
| EP-2582688-A1 | ANTHRANILIC ACID DIAMIDE DERIVATIVES | Bayer Intellectual Property GmbH (DE) | 2013-04-24 | — | — | EP | disclosed |
| US-20120015980-A1 | ANTHRANILIC DIAMIDE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2012-01-19 | — | — | US | disclosed |
| WO-2011157654-A1 | ANTHRANILIC ACID DIAMIDE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015980-A1 | ANTHRANILIC DIAMIDE DERIVATIVES | DDT, QDPR, ANTXR2 | TRPV1 2761/4885NPY5R 443/4885TRPA1 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.